Skip to main content

Advertisement

SpringerLink
Log in

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Bortezomib, a selective inhibitor of the 20S proteasome with activity in a variety of cancers, exhibits sequence-dependent synergistic cytotoxicity with taxanes and platinum agents. Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity.

Methods

Patients with advanced malignancies were alternately assigned to receive (schedule A) paclitaxel and carboplatin (IV d1) followed by bortezomib (IV d2, d5, d8) or (schedule B) bortezomib (IV d1, d4, d8) followed by paclitaxel and carboplatin (IV d2) on a 21-day cycle.

Results

Fifty-three patients (A 25, B 28) were treated with a median of 3 cycles (range 1–8) for schedule A and 3.5 cycles (range 1–10) for schedule B. Grade 3 or higher treatment related hematologic adverse events in all cycles of treatment included neutropenia (A 52%, B 50%), anemia (A 12%, B 7.1%) and thrombocytopenia (A 16%, B 17.9%). Non-hematologic treatment related adverse events were fairly mild (primarily grades 1 and 2). The maximum tolerated dose and the recommended doses for future phase II trials are bortezomib 1.2 mg/m2, paclitaxel 135 mg/m2 and carboplatin AUC = 6 for schedule A and bortezomib 1.2 mg/m2, paclitaxel 175 mg/m2 and carboplatin AUC = 6 for schedule B. Six (21.4%) partial responses (PR) were seen with schedule B. In contrast, only 1 (4%) PR was achieved with schedule A. Similar proteasome inhibition was achieved at MTD for both schedules.

Conclusion

Administration of sequential bortezomib followed by chemotherapy (schedule B) was well tolerated and associated with an encouraging number of objective responses in this small group of patients. Further studies with this administration schedule are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274:1652–1659

    Article  PubMed  CAS  Google Scholar 

  2. Voorhees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Ann Rev Pharmacol Toxicol 46:189–213

    Article  CAS  Google Scholar 

  3. Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505–2511

    PubMed  CAS  Google Scholar 

  4. Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108–2121

    Article  PubMed  CAS  Google Scholar 

  5. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617

    Article  PubMed  CAS  Google Scholar 

  6. Goy AH, East K, Mesina O et al (2003) Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas. Proc Am Soc Clin Oncol 22:570

    Google Scholar 

  7. Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420–4427

    Article  PubMed  CAS  Google Scholar 

  8. O’Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 23:676–684

    Article  PubMed  CAS  Google Scholar 

  9. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41–48

    Article  PubMed  CAS  Google Scholar 

  10. Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508–513

    Article  PubMed  Google Scholar 

  11. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638–2645

    PubMed  CAS  Google Scholar 

  12. Cusack JCJ, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-[kappa]B inhibition. Cancer Res 61:3535–3540

    PubMed  CAS  Google Scholar 

  13. Shah SA, Potter MW, McDade TP et al (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110–122

    Article  PubMed  CAS  Google Scholar 

  14. Bold RJ, Virudachalam S, McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11–17

    Article  PubMed  CAS  Google Scholar 

  15. Pink M, Pien CS, Worland P (2002) PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 43:158

    Google Scholar 

  16. Goy A, Remache Y, Barkoh B, Jiang Y, Hart S, Gilles F (2004) Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-hodgkin’s lymphoma cells. Session Type. American Society of Hematology 46th Annual Meeting Abstract no. 1387

  17. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ (2004) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54:343–353

    Article  PubMed  CAS  Google Scholar 

  18. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ (2003) Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 113:88–95

    Article  PubMed  CAS  Google Scholar 

  19. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR (2003) Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 41:89–96

    Article  Google Scholar 

  20. Garfield D (2001) Proteasome inhibitor PS-341 and docetaxel: sequence of administration may be crucial. Lancet Oncol 2:714

    Article  Google Scholar 

  21. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422

    PubMed  CAS  Google Scholar 

  22. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673–683

    PubMed  CAS  Google Scholar 

  23. Dy GK, Thomas JP, Wilding G et al (2005) A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11:3410–3416

    Article  PubMed  CAS  Google Scholar 

  24. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23:5943–5949

    Article  PubMed  CAS  Google Scholar 

  25. Dong QG, Sclabas GM, Fujioka S et al (2002) The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21:6510–6519

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Cynthia Ma, Sumithra J. Mandrekar, Steven R. Alberts, Gary A. Croghan, Aminah Jatoi, Joel M. Reid, Lorelei J. Hanson, Laura Bruzek, Angelina D. Tan, Henry C. Pitot, Charles Erlichman & Alex A. Adjei

  2. National Cancer Institute, Bethesda, MD, USA

    John J. Wright

Authors
  1. Cynthia Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumithra J. Mandrekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven R. Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gary A. Croghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aminah Jatoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joel M. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lorelei J. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laura Bruzek
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Angelina D. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Henry C. Pitot
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Charles Erlichman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. John J. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alex A. Adjei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex A. Adjei.

Additional information

Supported in part by grants: CA69912 and RR00585 from the National Institutes of Health.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, C., Mandrekar, S.J., Alberts, S.R. et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59, 207–215 (2007). https://doi.org/10.1007/s00280-006-0259-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0259-9

Keywords

Search

Navigation